iBreastExam®

Early Detection. For All.

Over 1.5 million women examined worldwide

—

Health Equity Innovation backed by multiple publications

—

Globally recognized award-winning technology

An innovation from
UE LifeSciences

Marketed & distributed by
molbio®
INNOVATE • IMPACT • INSPIRE

Ultra Portable Hand-held Breast Exam

iBreastExam® is an FDA-cleared, hand-held device that enables health workers to identify breast lumps in just minutes — without pain, radiation, or complex infrastructure.

648 Dynamic Co-Planar Capacitive, DCPC sensors (patent pending) measure tissue elasticity 20 times per second.



iBreastExam® Connect App reports clinically relevant breast lesions immediately, at PoC.



iBreastExam® Global Dashboard

Secure, versatile and feature-rich cloud based repository of every scan.

25,000+
women enrolled across 10+ independent international investigator initiated publications

2M+ Scans supplied in 12 countries

Clinical Validation*

Clinical Study Title, Publication	Sensitivity	Specificity	NPV	Benchmarked By
Study of Accuracy of iBreastExam as a Screening Modality to Detect Breast Lumps, IJCIR	88%	94%	95%	MMG, CBE
Non-invasive and low-cost technique for early detection of clinically relevant breast lesions, Ann. Oncol.	84%	94%	98%	MMG, USG
Clinical efficacy evaluation of a novel palpation imaging device for early detection of breast cancer in the developing world, SABCS	86%	91%	98%	MMG, USG
A cost-effective handheld breast scanner for use in low-resource environments, WJSO	86%	89%	96%	MMG, USG
Breast Tumor Detection using Piezoelectric Fingers: First Clinical Report, J Am Coll Surg	83%	88%	75%	MMG
Diagnostic accuracy of a novel palpation device to improve early detection of breast cancer in low resource settings, SABCS	74%	88%	N/A	MMG, USG
Clinical Utility of a Hand-Held Scanner for Breast Cancer Early Detection and Patient Triage, JCO (ASCO)	N/A	80%	94%	MMG, CBE
The iBreastExam versus clinical breast examination for breast evaluation in high risk and symptomatic Nigerian women, Lancet Global Health	86%	50%	98%	MMG, USG, CBE

*Using both Gen 1 and Gen 2 iBreastExam sensor technology

Affordable early stage identification with minimal training



Clinical Workflow

iBreastExam®
Ex: **1,000 women**

Targeted USG/MMG
5% positive
(50 women)

FNA / Biopsy
0.5% positive
(5 women)

Sensitivity - 86%*
Specificity - 91%*
NPV - 98%*

*Data Presented at 2019 San Antonio Breast Cancer Symposium

molbio®

MOLBIO DIAGNOSTICS LIMITED
L-46, Phase II D, Verna Industrial Estate
Verna, Goa - 403 722, India

+91 832-2783267
sales@molbiodiagnostics.com
www.molbiodiagnostics.com
customersupport@molbiodiagnostics.com

Showcased in

Rewriting Cancer
BBC StoryWorks Commercial Productions
UICC

Molecules of Hope
JioHotstar

Recognized by

World Health Organization as Innovative Health Technology

World Bank as Global Women's HealthTech Awardee

World Economic Forum as Top Innovator

Featured in

The New York Times
Forbes Asia
BBC WORLD NEWS
TED

"Until the required infrastructure and quality control measures are established, breast cancer screening in LMICs might require focusing on affordable, easy-to-use, alternative solutions, such as the iBreastExam."

THE LANCET Oncology

FDA Cleared